Current:Home > NewsUnanimous Supreme Court preserves access to widely used abortion medication -前500条预览:
Unanimous Supreme Court preserves access to widely used abortion medication
View
Date:2025-04-24 16:41:21
Live updates: Follow AP’s coverage of the Supreme Court’s decision to preserve access to mifepristone.
WASHINGTON (AP) — The Supreme Court on Thursday unanimously preserved access to a medication that was used in nearly two-thirds of all abortions in the U.S. last year, in the court’s first abortion decision since conservative justices overturned Roe v. Wade two years ago.
The justices ruled that abortion opponents lacked the legal right to sue over the federal Food and Drug Administration’s approval of the medication, mifepristone, and the FDA’s subsequent actions to ease access to it.
The case had threatened to restrict access to mifepristone across the country, including in states where abortion remains legal.
Justice Brett Kavanaugh wrote for the court that “federal courts are the wrong forum for addressing the plaintiffs’ concerns about FDA’s actions.” Kavanaugh was part of the majority to overturn Roe.
The high court is separately considering another abortion case, about whether a federal law on emergency treatment at hospitals overrides state abortion bans in rare emergency cases in which a pregnant patient’s health is at serious risk.
More than 6 million people have used mifepristone since 2000. Mifepristone blocks the hormone progesterone and primes the uterus to respond to the contraction-causing effect of a second drug, misoprostol. The two-drug regimen has been used to end a pregnancy through 10 weeks gestation.
Health care providers have said that if mifepristone is no longer available or is too hard to obtain, they would switch to using only misoprostol, which is somewhat less effective in ending pregnancies.
President Joe Biden’s administration and drug manufacturers had warned that siding with abortion opponents in this case could undermine the FDA’s drug approval process beyond the abortion context by inviting judges to second-guess the agency’s scientific judgments. The Democratic administration and New York-based Danco Laboratories, which makes mifepristone, argued that the drug is among the safest the FDA has ever approved.
The decision “safeguards access to a drug that has decades of safe and effective use,” Danco spokeswoman Abigail Long said in a statement.
The abortion opponents argued in court papers that the FDA’s decisions in 2016 and 2021 to relax restrictions on getting the drug were unreasonable and “jeopardize women’s health across the nation.”
Kavanaugh acknowledged what he described as the opponents’ “sincere legal, moral, ideological, and policy objections to elective abortion and to FDA’s relaxed regulation of mifepristone.”
But he said they went to the wrong forum and should instead direct their energies to persuading lawmakers and regulators to make changes.
Those comments pointed to the stakes of the 2024 election and the possibility that an FDA commissioner appointed by Republican Donald Trump, if he wins the White House, could consider tightening access to mifepristone.
The mifepristone case began five months after the Supreme Court overturned Roe. Abortion opponents initially won a sweeping ruling nearly a year ago from U.S. District Judge Matthew Kacsmaryk, a Trump nominee in Texas, which would have revoked the drug’s approval entirely. The 5th U.S. Circuit Court of Appeals left intact the FDA’s initial approval of mifepristone. But it would reverse changes regulators made in 2016 and 2021 that eased some conditions for administering the drug.
The Supreme Court put the appeals court’s modified ruling on hold, then agreed to hear the case, though Justices Samuel Alito, the author of the decision overturning Roe, and Clarence Thomas would have allowed some restrictions to take effect while the case proceeded.
___
Follow the AP’s coverage of the U.S. Supreme Court at https://apnews.com/hub/us-supreme-court.
veryGood! (1)
Related
- Sam Taylor
- Here’s what to know about Turkey’s decision to move forward with Sweden’s bid to join NATO
- Are They on Top? Checking In With the Winners of America's Next Top Model Now
- Disney says in lawsuit that DeSantis-appointed government is failing to release public records
- Toyota to invest $922 million to build a new paint facility at its Kentucky complex
- Widower of metro Phoenix’s ex-top prosecutor suspected of killing 2 women before taking his own life
- Not everyone's holiday is about family. Christmas traditions remind me what I've been missing.
- Not everyone's holiday is about family. Christmas traditions remind me what I've been missing.
- Taylor Swift Eras Archive site launches on singer's 35th birthday. What is it?
- Teen's death in Wisconsin sawmill highlights 21st century problem across the U.S.
Ranking
- Which apps offer encrypted messaging? How to switch and what to know after feds’ warning
- How removing 4 dams will return salmon to the Klamath River and the river to the people
- 9,000 state workers in Maine to see big bump in pay in new year
- The year in clean energy: Wind, solar and batteries grow despite economic challenges
- North Carolina justices rule for restaurants in COVID
- Authorities identify remains found by hikers 47 years ago near the Arizona-Nevada border
- Want to run faster? It comes down to technique, strength and practice.
- Pistons try to avoid 27th straight loss and a new NBA single-season record Tuesday against Nets
Recommendation
Woman dies after Singapore family of 3 gets into accident in Taiwan
Mexico’s army-run airline takes to the skies, with first flight to the resort of Tulum
US online retailer Zulily says it will go into liquidation, surprising customers
Horoscopes Today, December 26, 2023
Jamie Foxx reps say actor was hit in face by a glass at birthday dinner, needed stitches
'The Simpsons' makes fun of Jim Harbaugh, Michigan football scandals in latest episode
Pistons try to avoid 27th straight loss and a new NBA single-season record Tuesday against Nets
Manchester United says British billionaire buys minority stake